M.D. Anderson Cancer Center: Osteosarcoma trials
The registry lists 11 Osteosarcoma studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 2 have results posted.
Phase 1 4Phase 2 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2
- Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary MetastasesRecruitingNCT03093909Phase 1
- Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in OsteosarcomaCompletedNCT01833520Phase 1/2Results posted
- Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient ChemotherapyTerminatedNCT00673179Not applicableResults posted
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingNCT04668300Phase 2
- Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory OsteosarcomaActive, not recruitingNCT03598595Phase 1/2
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
- Aerosolized Aldesleukin in Treating Patients With Lung MetastasesActive, not recruitingNCT01590069Phase 1/2
- Retrospective Study of the Biomechanical Properties of Large AllograftsTerminatedNCT00632294
- Recombinant Interferon Alpha and Etoposide in Relapsed OsteosarcomaCompletedNCT00504140Phase 2
- Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed MalignanciesCompletedNCT00038207Phase 2